Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.

INTRODUCTION: Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. PATIENTS AND METHODS: This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies. RESULTS: A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml. CONCLUSION: The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.

Renal primary angiosarcoma.

Angiosarcomas account for 2% of all soft tissue sarcomas and of them, primary renal angiosarcomas represent 1%. Twenty-four cases have been published in the English specialised literature. We report the second case to be described in a middle-aged female, with pulmonary metastases at diagnosis, and fatal outcome despite surgery and chemotherapy.

Renal primary angiosarcoma

Angiosarcomas account for 2% of all soft tissue sarcomas and of them, primary renal angiosarcomas represent 1%. Twenty-four cases have been published in the English specialised literature. We report the second case to be described in a middle-aged female, with pulmonary metastases at diagnosis, and fatal outcome despite surgery and chemotherapy (AU)

Carcinoma epidermoide de mama (descripción de un caso y revisión de la literatura) / Breast epidermoid carcinoma: report of a case and review of the literature

El carcinoma epidermoide primario de mama esuna entidad muy poco frecuente. Típicamente sepresenta como un tumor cístico en la mama de grantamaño y evolución rápida. (También se caracterizapor diseminación a distancia y escasa afectaciónmetastásica en ganglios). En la mayoría de los casos,los receptores hormonales son negativos y loshallazgos radiológicos son inespecíficos. Los tratamientosdescritos en la literatura consisten en lacombinación de cirugía, quimioterapia y radioterapia

Breast primary squamous carcinoma is an infrequententity. It appears typically as a voluminousbreast cystic tumour of rapid evolution. It is characteristicthe development of a systemic disseminationgenerally in the absence of regional lymph nodemetastases. In most cases hormone receptors arelacking, and radiological findings are not specific.The treatments described in the medical literatureconsist of a combination of surgery, chemotherapyand radiotherapy